II. History
- Sir James Black and Propranolol
- Sir James Black won 1988 Nobel Prize for Propranolol
- Synthesized Propranolol first in the 1960's
- Revolutionized cardiovascular medicine
III. Indications
-
Hypertension
- Not first line for Hypertension unless other comorbid cardiovascular indications (e.g. Coronary Artery Disease, chronic stable CHF)
- Atrial Fibrillation Rate Control
- Coronary Artery Disease without prior Myocardial Infarction
-
Myocardial Infarction (esp. with reduced ejection fraction <50%)
- Continue for at least 1 year after Myocardial Infarction (previously recommended for 3 years)
- Primary benefit in Post-MI is for those with reduced ejection fraction (<50%)
- Post-MI with revascularization and preserved ejection fraction appears to benefit little from Beta Blockers
- Yndigegn (2024) N Engl J Med 390(15):1372-81 +PMID: 38587241 [PubMed]
- Stable Congestive Heart Failure (Carvedilol, Metoprolol, Bisoprolol)
- Continue Beta Blocker indefinately
-
Arrhythmia refractory to other modality
- Recurrent Ventricular Tachycardia
- Recurrent Ventricular Fibrillation
- Migraine Prophylaxis
- Endocrinopathy
- Thyroid Storm
- Pheochromocytoma
- Never use Beta Blocker without Alpha Adrenergic ReceptorAntagonist in Pheochromocytoma
- Open Angle Glaucoma
IV. Contraindications
- Reactive Airway Disease and Obstructive Lung Disease (Asthma, COPD)
- Cardioselective Beta Blockers (e.g. Metoprolol) are not contraindicated in COPD
- Do not reduce effectiveness of beta Agonists (Bronchodilators)
- Recommended for decreased mortality, decreased Tachycardia with beta Agonists
- Avoid non-selective Beta Blockers (Carvedilol, Propranolol)
- See Bronchospasm under adverse effects below
- Cardioselective Beta Blockers (e.g. Metoprolol) are not contraindicated in COPD
- Acute Congestive Heart Failure exascerbation (decompensated CHF)
- Concurrent Non-Dihydropyridine Calcium Channel Blocker (e.g. Diltiazem, Verapamil) use
- Relative contraindication (risk of AV Block, Bradycardia)
V. Precautions
- Abrupt discontinuation is associated with exacerbation of Angina and risk of MI (FDA black box warning)
- Taper over one to two weeks
VI. Mechanism: General
- Beta Adrenergic Receptor Antagonist
- Inhibits effects of circulating Catecholamines
- Blocks Beta Adrenergic Receptors
- Beta-1 Adrenergic Receptors (Selective Beta Blockers primarily inhibit B1)
- Beta-2 Adrenergic Receptors
- Smooth Muscle and Bronchioles
- Beta-3 Adrenergic Receptors
- Lipolysis
VII. Mechanism: Cardiovascular Specific (Beta-1 Adrenergic Receptor blockade)
-
General Cardiac Effects
- Negative Inotrope
- Reduces Myocardial Contractility
- Negative Chronotrope
- Reduces Heart Rate
- Reduces Blood Pressure
- Reduces Myocardial Oxygen Demand
- Negative Inotrope
-
Antiarrhythmic effects
- Controls Catecholamine stimulated Arrhythmias
- Recurrent Ventricular Tachycardia
- Recurrent Ventricular Fibrillation
- Controls Myocardial Ischemia related Arrhythmias
- Reduces AV Nodal Conduction
- Slows ventricular response
- Quinidine-like effect on Action Potential
- Seen with Propranolol
- Controls Catecholamine stimulated Arrhythmias
- Myocardial protection
- Reduces Myocardial Infarction size
- Prevents re-infarction after Thrombolytic
VIII. Mechanism: Non-Selective effects (non-cardiovascular effects)
-
Beta 2 Adrenergic Receptor blockade
- Results in bronchoconstriction
- Beta 2 Adrenergic Receptors affect Bronchiole and Smooth Muscles
- Non-Selective Beta Blockers (e.g. Propranolol)
- Selective Beta Blockers lose selectivity at high dose and in Overdose
- High dose Metoprolol (over 200 mg/day)
- High dose Esmolol (over 300 ug/kg/min)
- Results in bronchoconstriction
- Beta 3 Adrenergic Receptor blockade
- Lipolysis inhibited
IX. Adverse Effects
- SA and AV nodal blockade
- Avoid in over age 75 unless secondary indication
- Do not use with Calcium Channel Blockers
- Hypotension or Orthostasis
-
Congestive Heart Failure
- Treat with vasodilators and Diuretics with inotropes
-
Bradycardia
- Treat with Atropine, Transcutaneous Pacing, Dopamine
- Bronchospasm
- Treat with Sympathomimetics and Aminophylline
- Unlikely to occur in cardioselective Beta Blockers at standard doses
- Study looked at Atenolol, Metoprolol, Bisoprolol
- First dose may lower FEV1 (responds to Albuterol)
- Continuous use does not impair lung function
- Salpeter (2002) Ann Intern Med 137:715-25 [PubMed]
- Major Depression exacerbation
- Fatigue
X. Drug Interactions
- Decreased Heart Rate and AV Conduction (cummulative effects of multiple agents acting at AV Node)
- Beta Blockers potentiate effects of other agents
XI. Preparations: Cardioselective (Beta-1 Selective Adrenergic Blockade)
-
Atenolol (Tenormin)
- Despite daily dosing, duration of activity is not a a full 24 hours
- Consider dividing dosing into twice daily (e.g. 50 mg twice daily)
- Not as effective as other Beta Blockers in cardiovascular disease prevention (especially with Hypertension present)
- Consider Metoprolol, Bisoprolol, Carvedilol or Nadolol instead
- Carlberg (2004) Lancet 364:1684-9 [PubMed]
- Dosing Adults
- Start: 25-50 mg orally daily
- Target: 50-100 mg orally daily (may divide dose twice daily)
- Maximum dose: 100 mg (50 mg if GFR <35 ml/min, 25 mg if GFR <15 ml/min)
- Despite daily dosing, duration of activity is not a a full 24 hours
-
Metoprolol (Lopressor, Toprol XL)
- See Metoprolol
- Preferred Beta Blocker for Hypertension, Myocardial Infarction, Atrial Fibrillation Rate Control
- Metoprolol Succinate (Toprol XL) is preferred over Metoprolol Tartrate (Lopressor)
-
Bisoprolol (Zebeta)
- Most cardioselective of Beta Blockers
- Start: 2.5 to 5 mg orally daily
- Maximum: 20 mg/day
-
Betaxolol (Kerlone)
- Start: 5 mg orally daily
- Maximum: 20 mg/day
-
Acebutolol (Sectral)
- Intrinsic Sympathomimetic activity (partial beta Agonist)
- Start: 400 mg orally daily or divided 200 mg orally twice daily
- Better efficacy when divided twice daily
- Target: 400 to 800 mg/day
- Maximum: 1200 mg/day
XII. Preparations: Nonselective (Beta-1 and Beta-2 Adrenergic Blockade)
-
Timolol (Blocadren)
- Dose: 10 mg orally twice daily (maximum 60 mg/day)
-
Nadolol (Corgard)
- Dose: 40 mg orally daily (maximum 320 mg/day)
- Decrease dose with Renal Insufficiency
-
Propranolol (Inderal)
- Used for Essential Tremor, symptomatic Hyperthyroidism, Migraine Prophylaxis, symptomatic Palpitations
-
Timolol
- See Intraocular Beta Blocker
- Typically used topically for Open Angle Glaucoma
- Longer half life than Propranolol
-
Sotalol
- Primarily used as Antiarrhythmic
- Penbutalol (Levatol)
- Start: 20 mg orally daily
- Target: 20-40 mg orally daily
- Maximum: 80 mg/day
- Oxprenolol
- Dose: 80-160 mg orally divided twice to three times daily
- Maximum: 320 mg/day
- Carteolol (Cartrol)
- Start: 2.5 mg orally daily
- Target: 2.5 to 5 mg orally daily
- Maximum: 10 mg/day
- GFR <60: decrease dose to every 48 hours
-
Pindolol (Visken)
- Intrinsic Sympathomimetic activity (partial beta Agonist), similar to Acebutolol
- Start: 5 mg orally twice daily
- Target: 5 to 15 mg orally twice daily
- Maximum: 60 mg/day
XIII. Preparations: Combined Beta Blocker and Vasodilator
- Combined Alpha-1, Beta-1 and Beta-2 Adrenergic Blockade
- Labetalol
- Carvedilol (Coreg)
- Third generation Beta Blocker with vasodilatory properties (alpha blocker)
- Used in Congestive Heart Failure
- Combined Beta-1 and NItric Oxide (Beta-3 Agonist)
- Nebivolol (Bystolic)
- Third generation Beta Blocker with vasodilatory properties (nitric oxide release)
- Dosing
- Start: 5 mg orally (2.5 mg in hepatic Impairment or GFR <30 ml/min)
- Maximum: 40 mg/day
- Nebivolol (Bystolic)
XIV. Preparations: Parenteral Beta Blockers
- Metoprolol
- Labetalol
-
Esmolol Hydrochloride (Brevibloc)
- See Esmolol
- Intravenous very short acting, Beta-1 Selective Beta Blocker
- See Emergent Hypertension Management (esp. Aortic Dissection)
XV. References
- (2012) Presc Lett 19(12): 67-8
- Yen (2015) Crit Dec Emerg Med 29(10): 18-23
Images: Related links to external sites (from Bing)
Related Studies
carteolol (on 9/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CARTEOLOL HCL 1% EYE DROPS | Generic | $1.19 per ml |